Biotechnology (21) | Waiver Agreements (21)
Browse by Company
Recent Contracts
-
Waiver dated June 13, 2022
(TENAX THERAPEUTICS, INC., Filed With SEC on June 16, 2022)
-
Waiver and Amendment Letter, dated May 23, 2022
(OPGEN INC, Filed With SEC on May 24, 2022)
-
Form of Waiver Agreement
(AzurRx BioPharma, Inc., Filed With SEC on May 13, 2022)
-
Form of Waiver
(CLEVELAND BIOLABS INC, Filed With SEC on March 22, 2022)
-
Form of Waiver
(AzurRx BioPharma, Inc., Filed With SEC on February 7, 2022)
-
Waiver and Amendment between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt, dated November 29, 2021
(RITTER PHARMACEUTICALS INC, Filed With SEC on December 1, 2021)
-
Waiver and Defeasance Agreement
(ADiTx Therapeutics, Inc., Filed With SEC on August 30, 2021)
-
Form of Waiver Agreement, dated as of February 3, 2021, by and between Ocuphire Pharma, Inc. and the Holder(s)
(REXAHN PHARMACEUTICALS, INC., Filed With SEC on February 4, 2021)
-
Fee Waiver Letter, dated January 31, 2021
(Leisure Acquisition Corp., Filed With SEC on February 2, 2021)
-
Waiver, dated January 20, 2021, by and among Cerevel Therapeutics Holdings, Inc. and the investors party thereto
(ARYA Sciences Acquisition Corp II, Filed With SEC on January 21, 2021)